The Fragile X mental retardation protein (FMRP) regulates neuronal RNA metabolism, and its absence or mutations leads to the Fragile X syndrome (FXS). The b-amyloid precursor protein (APP) is involved in Alzheimer's disease, plays a role in synapse formation, and is upregulated in intellectual disabilities. Here, we show that during mouse synaptogenesis and in human FXS fibroblasts, a dual dysregulation of APP and the a-secretase ADAM10 leads to the production of an excess of soluble APPa (sAPPa). In FXS, sAPPa signals through the metabotropic receptor that, activating the MAP kinase pathway, leads to synaptic and behavioral deficits. Modulation of ADAM10 activity in FXS reduces sAPPa levels, restoring translational control, synaptic morphology, and behavioral plasticity. Thus, proper control of ADAM10-mediated APP processing during a specific developmental postnatal stage is crucial for healthy spine formation and function(s). Downregulation of ADAM10 activity at synapses may be an effective strategy for ameliorating FXS phenotypes.
Correspondence claudia.bagni@cme.vib-kuleuven.be In Brief Pasciuto et al. show that dual dysregulation of APP and ADAM10, during a critical period of postnatal development, leads to overproduction of sAPPa. Modulation of ADAM10 activity re-establishes physiological sAPPa levels and ultimately ameliorates FXS molecular, synaptic, and behavioral deficits.
INTRODUCTION
Brain development is a life-long project. While it is well accepted that the brain undergoes critical periods in its development, the molecular basis of these critical periods is not fully understood. The events that shape the brain during development influence processing of new information, acquisition of new skills, and formation of memories throughout life. Proper synaptic contacts, trans synaptic signaling, and structural remodeling are essential aspects of synapse maturation and stabilization during postnatal brain development (Grant, 2012; Yuste, 2013) . Fine-tuned expression of several proteins is fundamental for the synaptic structure, the establishment of synaptic networks, and neuronal plasticity (Sala and Segal, 2014) . Changes in dendritic spine morphology and plasticity are associated with various neurodevelopmental diseases, such as Down syndrome, Rett syndrome, autism spectrum disorder (ASD), and Fragile X syndrome (FXS) (Sala and Segal, 2014) .
FXS is the most common form of inherited intellectual disability and about 30% of FXS children meet the criteria for ASD (Jacquemont et al., 2007; Lozano et al., 2014) . Patients with FXS have cognitive and behavioral deficits, anxiety, and a susceptibility to epilepsy (Jacquemont et al., 2007; Lozano et al., 2014) . At the cellular level, FXS neurons have an increased number of dendritic spines that appear long, thin, and tortuous (Hinton et al., 1991; Irwin et al., 2001 ). The mouse model of FXS (Fmr1 knockout [KO] ) exhibits morphological, synaptic, and behavioral alterations similar to human patients (Bakker, 1994; Comery et al., 1997; Huber et al., 2002; Santos et al., 2014) .
FXS is due to the absence of, or mutations in, the Fragile X mental retardation protein, FMRP, an RNA-binding protein.
Through four RNA-binding domains, FMRP associates with messenger RNAs (mRNAs) encoding pre-and postsynaptic proteins and regulates multiple steps of mRNA metabolism, such as dendritic transport, stability, and translation (Darnell and Klann, 2013; Bagni, 2014a, 2014b) . Loss of FMRP compromises the fine-tuned expression of a variety of proteins, leading to deficits in embryonic and early postnatal brain wiring networks (La Fata et al., 2014; Romano et al., 2014) . Mutations in several of the FMRP target mRNAs are associated with different forms of intellectual disability such as ASD, mood disorders, and schizophrenia (Pasciuto and Bagni, 2014b) . A mechanism through which FMRP inhibits translation of synaptic mRNAs is via the cytoplasmic FMRP interacting protein 1 (CYFIP1) that acts as an eIF4E-binding protein (De Rubeis et al., 2013; Genheden et al., 2015; Napoli et al., 2008; Panja et al., 2014) . Among the bona-fide mRNAs regulated by FMRP (Pasciuto and Bagni, 2014b ) is the transcript encoding the amyloid precursor protein (APP) (Napoli et al., 2008; Westmark and Malter, 2007) . APP is a type I transmembrane protein that plays a central role in Alzheimer's disease (AD) (Rajendran and Annaert, 2012) and is also dysregulated in neurodevelopmental disorders, such as Down syndrome (Glenner and Wong, 1984) , FXS, and ASD Westmark et al., 2011) . APP was initially described as a cell-surface receptor (Kang et al., 1987) that interacts with a variety of molecules and some components of the extracellular matrix (Reinhard et al., 2013) , thus activating transmembrane signal transduction, calcium metabolism, and/ or transcription (Mü ller and Zheng, 2012; Rice et al., 2013) . A wide range of APP functions have been described in both the developing and adult brain, including neurite outgrowth, synaptic development and plasticity, cell adhesion, protein trafficking, and cell migration (Hoe et al., 2012; Mü ller and Zheng, 2012) . Consistent with its functions, APP expression is high during spine formation and progressively declines after synaptic maturation (Moya et al., 1994) . Alterations of synaptic structure and function are therefore well established features of APP dysregulation, although the underlying complex molecular mechanism(s) are poorly understood.
While impaired learning and memory and reduced long-term plasticity have been consistently found in aged App KO mice (Ring et al., 2007; Tyan et al., 2012) , the effects of APP deletion on dendritic spine density are quite controversial (Hoe et al., 2012) . Both increased (Bittner et al., 2009 ) and reduced mature spine density (Lee et al., 2010b; Tyan et al., 2012) have been reported in the cortex of APP-deficient mice. Overexpression of APP consistently increases spine number and promotes synaptogenesis (Lee et al., 2010b) .
On the cell surface, APP processing generates a secreted form of APP (sAPPa) and a C-terminal fragment (CTFa). Soluble APPa is upregulated during synaptogenesis and increases synaptic density, cortical synaptogenesis, and memory retention in vivo (Bell et al., 2008; Hick et al., 2015; Roch et al., 1994; Tyan et al., 2012) , and it has been proposed to have both a neurotrophic and neuroprotective effect (Milosch et al., 2014; Mü ller and Zheng, 2012) . The disintegrin metalloprotease ADAM10 is the constitutive a-secretase required for sAPPa generation (Kuhn et al., 2010) . Its function is essential for cortex formation and for spine morphology (Jorissen et al., 2010; Malinverno et al., 2010) . ADAM10 overexpression promotes cortical synaptogenesis (Bell et al., 2008) , whereas its depletion causes synaptic defects and impaired learning (Prox et al., 2013) . A different APP processing pathway, mediated by the b-secretase BACE1, cleaves APP, generating a soluble form of APP (sAPPb) and a C-terminal membraneassociated fragment (CTFb). The formation of b-amyloid (Ab40-42) in the brain is critical for AD progression (Karran et al., 2011; Selkoe, 2002) .
Here, we highlight the critical role played by FMRP in coordinating the production of sAPPa in the brain. Soluble APPa accumulates in the FXS brain as a result of excessive synthesis of APP and ADAM10 proteins during a critical postnatal period. The excess of generated sAPPa drives an increase in protein synthesis, formation of immature spines, and impaired synaptic plasticity. This cascade of events requires the metabotropic glutamate receptor 5 signaling and activates the mitogen-activated protein kinase (MAPK) pathway. Finally, we show that modulation of ADAM10 activity at FXS synapses ameliorates various molecular, synaptic, and behavioral defects in FXS.
RESULTS

FMRP Regulates APP Protein Processing at Early Postnatal Stages
The levels of APP are increased when FMRP is absent (Westmark and Malter, 2007) or when CYFIP1 levels are decreased in juvenile mice (Napoli et al., 2008) . Because FXS is a neurodevelopmental disorder, we characterized the changes of APP expression during brain development in the Fmr1 KO mouse model (Bakker, 1994) . Whole brain extracts from wild-type (WT) and Fmr1 KO mice were analyzed during early postnatal stages (P7, P14, and P21) and adulthood (P30 and P90). No differences in APP expression were observed between WT and KO mice at P7 and P14, whereas a significant upregulation was observed in the Fmr1 KO mice starting at 3 weeks after birth (P21) and was maintained throughout adulthood ( Figure 1A) . A similar dysregulation was observed at synapses ( Figure 1B) . App mRNA steady-state levels were not changed in the absence of FMRP ( Figure S1A) . Therefore, absence of FMRP leads to increased APP expression in the brain during a period critical for the stabilization of synapses and development of brain functions (Grant, 2012; Yuste, 2013) .
It has been hypothesized that the excess of APP in FXS might be pathogenic due to elevated Ab release (Westmark and Malter, 2007) . We measured Ab levels in cortex during synaptogenesis and in adulthood. Unexpectedly, we observed a significant decrease in Ab in juvenile Fmr1 KO mice compared to WT (Figure 2A) . Only at the adult stage are Ab levels increased (Figure 2A) . We next analyzed the production of secreted sAPP and CTFs using specific antibodies ( Figures S2A, S4B , and S4C). Brains were fractionated ( Figure S2B ) and the levels of sAPP (total sAPP, sAPPa, and sAPPb) quantified. Absence of FMRP leads to a parallel increase of APP and sAPP protein levels between the third and fifth postnatal week (P21-P30) (Figures 1A and 2B) . Specifically, we found a rise in sAPPa levels in juvenile (P21) Fmr1 KO mice and a decrease in b-cleavage (less sAPPb; Figure 2C ). We next investigated APP processing at FXS synapses by measuring the CTFs generated in the synaptic membrane. Using an established biochemical synaptosome fractionation (Galli et al., 1996; Marcello et al., 2007) , we isolated detergent resistant membrane from synaptoneurosomes (DRM; Figure S2C ). These samples are enriched in membrane-associated proteins, such as Synaptophysin, PSD95, Flotillin, and NMDA receptor subunits. We found that APP protein levels were less abundant in the synaptic membranes isolated from Fmr1 KO ( Figure 2D ). In the absence of FMRP, the levels of CTFa (10 kDa) generated by a-secretase activity were increased, whereas CTFb (12 kDa), the b-secretase product, was decreased ( Figure 2D ). The altered CTFa/CTFb ratio suggests that a-secretase activity is specifically upregulated in juvenile Fmr1 KO animals. Because a-and b-secretases compete to cleave APP, the observed reduction of sAPPb, CTFb, and Ab supports a skewed APP processing toward the non-amyloidogenic pathway in the Fmr1 KO during early stages of development and a possible switch toward the b-cleavage at later stages.
Absence of FMRP Reduces Cell-Surface APP Protein Levels The concomitant increase in sAPPa and decrease of sAPPb protein levels in the Fmr1 KO suggested that APP was highly processed at the cell surface. First, we determined total and surface APP levels in cortical neurons from WT and KO mice by immunofluorescence ( Figure 2E ). Total APP levels were detected by an antibody against the cytoplasmic domain (A8717; Figures S2A and S2B ) and the surface level of APP using an antibody against its ectodomain (22C11; Figures S2A and S2B). Total APP levels were higher in Fmr1 KO than in WT cortical neurons, as in brain extracts, but the surface APP was lower in the FMRP-deficient cells ( Figure 2E ). To corroborate our data, we biotinylated and captured cell-surface proteins and analyzed the precipitate by western blotting (WB) (Figure 2F) . Although the total APP expression was increased in Fmr1 KO mice, the surface APP was decreased. Both experiments showed that, in FMRP-deficient neurons, the global expression of APP is increased; however, there is a steep decrease in full-length APP protein levels at the cell surface (Figures 2E and 2F) . While we cannot rule out that a defect in APP trafficking could also contribute to the reduced APP present at the cell surface, the decrease in surface APP and the parallel increase in sAPP released in the media of Fmr1 KO neurons (Figure 2G ) strongly support that APP processing at the membrane is upregulated.
ADAM10 Protein Levels Are Upregulated in the Absence of FMRP
To identify the mechanisms underlying the decreased APP at the cell surface and the increased sAPPa release in FXS, we measured the expression levels of the constitutive APP The histograms show quantified protein levels normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). This ratio was set to 1 in the WT mice for each developmental stage. The bars represent the SEM (*p < 0.05; **p < 0.01, Student's t test) (n = 4 for each developmental stage). (B) APP levels are increased in Fmr1 KO synaptoneurosomes. Representative western blot showing protein levels at P7, P14, P21, P30, and P90 in WT and Fmr1 KO mice. The histograms show quantified APP expression normalized to GAPDH. This ratio in WT mice was set to 1. The bars represent the SEM (*p < 0.05; **p < 0.01, ***p < 0.001, Student's t test) (n = 3-4). See also Figure S1 . a-secretase ADAM10 (Jorissen et al., 2010) . WB of cortical (Figure 3A) and synaptic lysates ( Figure 3B ) showed a parallel increase in the expression of APP and mature ADAM10 in the absence of FMRP, while the synaptic expression of two other metalloproteases ADAM9 and 17 did not change ( Figure 3B) . Furthermore, the absence of FMRP leads to a developmental stage-specific increase of ADAM10 ( Figure 3C ), correlating with the increased production of sAPPa between the third and fourth postnatal week ( Figure 2B ). The increase of ADAM10 in Fmr1 KO cortical neurons was confirmed by immunofluorescence ( Figure 3D ). Opposite distribution to APP was observed for the mature ADAM10 protein, which was increased at the cell-surface ( Figure 3E ), where it cleaves APP to generate sAPPa (Lichtenthaler, 2011) . The increased ADAM10 expression in the Fmr1 KO mice, at this specific developmental stage, did not result in a dysregulation of other protein targets such as Notch and N-cadherin ( Figure S3 ).
Overall, these observations support the conclusion that FMRP, by coordinating both APP and ADAM10 expression, specifically regulates sAPPa generation during the critical period of synaptogenesis.
FMRP Regulates the ADAM10-APP Pathway at the Level of mRNA Translation
To test whether FMRP is directly involved in the generation of excessive levels of sAPPa, we investigated if FMRP directly regulates App and Adam10 mRNA metabolism in juvenile mice. FMRP was immunoprecipitated (IP) from brain extracts, and the bound mRNAs were analyzed by RT-PCR. App and Adam10 mRNAs were both associated with FMRP. The specificity of this interaction was confirmed by the absence of Adam9 and Adam17 mRNAs and the non-target D2DR and Cyp46 mRNAs ( Figure 3F ). App and Adam10 mRNA steadystate levels did not significantly change between WT and Fmr1 KO cortices ( Figure S1B ). Therefore, we assessed whether FMRP controls APP and ADAM10 protein synthesis. The mouse cortex was fractionated in translationally active polysomes and silent mRNPs and the mRNA distribution was analyzed as previously described (Zalfa et al., 2007) . As shown in Figure 3G , App and Adam10 mRNAs co-fractionated with the polysomal fraction more in the Fmr1 KO brain than in WT; in contrast, the levels of b-actin mRNA were unchanged, consistent with previous findings (Lee et al., 2010a) .
Our data indicate that FMRP regulates App and Adam10 mRNA translation. In the FXS mouse model, the lack of FMRPmediated translational repression increases APP and ADAM10 protein levels and ultimately generates the excess of sAPPa.
sAPPa Contributes to the FXS Spine Phenotype
To address the contribution of excessive APP synthesis and processing to the spine dysgenesis observed in FXS, we reduced APP in Fmr1 KO neurons (DIV 8), a stage in which neurons are still immature and APP is not dysregulated ( Figure S4A ). We knocked down APP using a lentiviral vector (Lee et al., 2010b ) carrying a short hairpin RNA directed specifically against App mRNA (App short hairpin [sh]RNA-EGFP; Figures S4B and S4C ). Mean spine head and length measurements were used to categorize the spines into the following classes: mushroom and stubby (mature); long thin and filopodia (immature) (Harris et al., 1992) (Figure S5A ). Reduction of APP in WT neurons reduced spine density, while exogenous sAPPa increased the number of immature spines ( Figures S5B and S5C ). The spine number and distribution along the four morphological classes significantly differed between WT and KO neurons, with the latter showing more immature spines (Figures 4 and S5C) . Importantly, when sAPPa was added to the medium of WT and Fmr1 KO neurons, in Fmr1 KO neurons, the APP-dependent rescue of the spine density was abolished and the density of long thin spines and filopodia increased ( Figures 4A-4C ), resulting in an increased number of immature spines ( Figures 4C and S5C ). In conclusion, these data support the hypothesis that concomitant deregulation of both APP expression and processing during the early stages of development contributes to immature spine formation in FMRP-deficient neurons. Of note, similar effects have been recently observed in ADAM10 heterozygous mice (Prox et al., 2013) , further supporting that the dual-level APP-ADAM10 is necessary for proper spine development and density.
Excessive ADAM10 Activity Causes Exaggerated Protein Synthesis in the Fmr1 KO Mice FXS mice have exaggerated protein synthesis (Bagni et al., 2012) . To explore whether sAPPa promotes protein synthesis in FXS, we used the SUnSET technology, a non-radioactive assay for labeling newly synthesized proteins (Schmidt et al., 2009) (Figure S6A ). The level of protein synthesis was monitored in cortical neurons and synaptoneurosomes from WT, Fmr1 KO, and Fmr1 KO/App heterozygous (Het) mice (Figures 5A and 5B) and in both cases protein synthesis was elevated in the absence of FMRP. Genetic reduction of APP in Fmr1 KO/App Het mice returned the protein synthesis rate to WT level ( Figure 5A ). App KO mice also showed a reduced protein synthesis at synapses, further supporting a role for APP in the regulation of translation in neurons ( Figure S6B ). Furthermore, treatment of WT and Fmr1 KO/App Het neurons with sAPPa led to an increase in protein synthesis (Figures 5C and 5D) . Treatment of WT neurons with sAPPb did not elicit protein synthesis (data not shown). To finally relate the sAPPa-dependent increase in protein synthesis to the excessive ADAM10 activity, we crossed the Fmr1 KO with the Adam10 Het mice and monitored basal protein synthesis at synapses. Genetic reduction of ADAM10 also lowered the rate of de novo protein synthesis in the Fmr1 KO ( Figure 5E ). Similarly, absence of ADAM10 in mouse embryonic fibroblasts ( Figure S6C ) and haploinsufficiency of ADAM10 in cortical neurons ( Figure S6D ) decreases protein synthesis. Taken together, these findings show that FXS mice have aberrant sAPPa-dependent de novo protein synthesis.
sAPPa Promotes Metabotropic Glutamate Receptor 5 Signaling Metabotropic glutamate receptor 5 (mGluR5) and MAPK signaling are affected in FXS (Osterweil et al., 2010) . To investigate a possible crosstalk between sAPPa-mediated increase in protein synthesis and mGluR5 activation, we treated cortical neurons with sAPPa and monitored the activation of the MAPK Figure 2 . Impaired Processing of APP in Fmr1 KO Mice Leads to Enhanced sAPPa Release (A) Ab40 levels in juvenile and aged Fmr1 KO cortices. The amount of Ab was measured by ELISA normalized to the brain's weight and expressed as the percentage of the WT. The bars represent the SEM (*p < 0.05, Student's t test) (n = 4 for both P21 and P300). (B) sAPP levels in KO brain cortices during postnatal development. The histograms show the quantification of sAPP protein levels normalized to Coomassie. The bars represent the SEM (*p < 0.05, **p < 0.01, Student's t test) (n = 3). (C) APP processing in P21 KO brain cortices. Representative WB showing protein levels of sAPP (sAPPa + sAPPb), sAPPa, and sAPPb in the soluble fraction (see also Figure S2 ) in WT and KO cortices. The histograms show the quantification of the three products normalized to Coomassie. The bars represent the SEM (*p < 0.05, one-sample t test) (n = 4). (D) a-and b-secretase products in WT and Fmr1 KO synaptic membranes. APP, APP CTFa (10 kDa) and CTFb (12 kDa), FMRP, and Vinculin protein levels were analyzed by WB in the synaptic membranes of WT and KO mice. The histograms show quantified proteins normalized to Vinculin. This ratio in WT mice was set to 1. The bars represent the SEM (*p < 0.05, **p < 0.01, one-sample t test) (n = 6). See also Figure S2 . (E) Cell-surface APP is reduced in Fmr1 KO cortical neurons. The WT and KO cortical neurons were stained for total APP (left) or surface APP (right). The representative dendritic fragments (>50 mm distance from the cell body) are shown. The histograms show the total and surface protein levels as the mean fluorescence intensity (Mean F.I.). The bars represent SEM (***p < 0.001, Student's t test) (n = 8 cells, five dendritic fragments [20 mm/cell]). The scale bar corresponds to 5 mm.
(legend continued on next page) signaling cascade downstream of mGluR5. Soluble APPa induced an increase in phosphorylated extracellular signalregulated kinase (ERK) 1/2 ( Figure 5F ). This was mediated via the activation of the mGluR1/5 receptor, because its effect was abolished by the mGluR5 antagonist MPEP ( Figure 5F ). Rapamycin treatment, affecting mTOR and ERK phosphorylation in opposite directions, was used as control (Ma and Blenis, 2009) . Interestingly, no effect on mTOR phosphorylation was observed upon sAPPa treatment or mGluR5 inhibition, suggesting that the mTOR pathway is not activated by sAPPa ( Figure 5F ).
Altogether, our data demonstrate that excessive production of sAPPa sustains the increase in mGluR-dependent protein synthesis observed in FXS, possibly through the MAPK signaling pathway. , which contains part of the intracellular domain of ADAM10; it interferes with the interaction of ADAM10 and synapse-associated protein 97 (SAP97), thereby reducing the localization and activity of ADAM10 specifically at the synapses (Marcello et al., 2007) . The treatment of WT and Fmr1 KO cortical neurons with TAT-Pro peptide reduced sAPPa release ( Figure 6A ). Consistently, we also reduced sAPP production in Fmr1 KO neurons using the tissue inhibitor of metalloproteinases (TIMP-1) (Amour et al., 2000) ( Figure S7A ). Furthermore, a treatment of the Fmr1 KO neurons with the TAT-Pro peptide increased the ratio of surface versus total APP levels ( Figure S7B ).
We next examined APP processing in juvenile (P21) WT and Fmr1 KO mice after intraperitoneal injection of the TAT-Pro peptide ( Figure 6B ). Importantly, the excessive sAPPa production in the Fmr1 KO mice, monitored by WB 18 hr after peptide injection, was no longer observed upon treatment with the peptide (Figure 6B ), suggesting that the excess is produced at FXS synapses; a control peptide (TAT-Ala) had no effect.
Because one of the hallmarks of FXS is the enhanced mGluRdependent long-term depression (LTD) observed in Fmr1 KO mice (Huber et al., 2002) , and ADAM10 activity affects LTD (Musardo et al., 2013; Prox et al., 2013) , we examined whether the reduction of ADAM10 activity could ameliorate the mGluR-LTD responses in Fmr1 KO mice. The effects of the TAT-Pro peptide on (RS)-3,5-Dihydroxyphenylglycine (DHPG) induced LTD were tested in juvenile (P18-25) WT and KO mice. Field excitatory postsynaptic potentials (fEPSPs) were recorded from CA1 neurons in hippocampal slices in response to Schaffer collateral fiber stimulation 18 hr after treatment. A bath application of DHPG (30 mM, 15 min) induced a robust LTD of fEPSPs in the WT slices (240 min: 53% ± 9% of baseline, n = 7). In agreement with previous reports (Nosyreva and Huber, 2005) , we observed an enhanced DHPG-induced LTD in the Fmr1 KO mice (240 min: 28% ± 3%, n = 12) ( Figure 6C ). Exposure to TAT-Pro or TAT-Ala peptides had no detectable effect on the ability of DHPG to elicit LTD in the WT slices (65% ± 8%, n = 7 and 56% ± 5%, n = 6, respectively) when compared with the untreated control ( Figure 6D ). These data correlate with lack of reduction of sAPPa levels upon TAT-Pro treatment in WT ( Figure 6B ). In contrast, we found that treatment with the TAT-Pro peptide was sufficient to prevent the enhanced LTD in the Fmr1 KO mice, indicating that the exaggerated late LTD (>2 hr) in these mice ( Figure 6E ) is a direct consequence of increased ADAM10 activity. Peptide treatment did not affect basal transmission ( Figures  S8A and S8B) .
To further address whether targeting ADAM10 could rescue the increased protein synthesis in FXS, WT and Fmr1 KO animals were treated in vivo with the TAT-Pro peptide. FMRP targets, such as APP, ADAM10, as well as the activity-regulated cytoskeleton-associated protein (ARC) and the striatal-enriched protein tyrosine phosphatase (STEP) (Bagni et al., 2012) were detected in synaptoneurosomes of treated animals ( Figure 6F ). We observed that upon injection of the TAT-Pro peptide, the excessive levels of APP, ADAM10, ARC, and STEP are restored to normality. These findings are consistent with the reduction of protein synthesis observed at the synapses of the Fmr1 KO/ Adam10
Het and Fmr1 KO/App Het mice ( Figures 5B and 5E ). Finally, we monitored the effect of the peptide on working memory (T-maze) and hyperactivity (open field) ( Figures 6G and 6H) , two behavioral features that have been consistently found altered in FXS mice (Santos et al., 2014) . Fmr1 KO mice move faster and travel a longer distance in the open field, and they fail more in the spontaneous alternation in the T-maze (Santos et al., 2014) . Nest building is a social behavior in mice impaired in Fragile X and other models of autism (Udagawa et al., 2013) . Fmr1 KO mice used less material in nest construction compared to WT animals ( Figure 6I ). Targeting ADAM10 trafficking with the TAT-Pro peptide ameliorates the above-mentioned behavioral deficits (Figures 6G-6I) .
Together, these results demonstrate that blocking SAP97-mediated ADAM10 trafficking to the synapses reduces sAPPa production and reverses molecular, cellular, and behavioral impairments that constitute the hallmarks of FXS.
FMRP Regulated APP and ADAM10 Protein Levels in Humans
To address the relevance of our findings for the human disease, APP and ADAM10 levels were analyzed in human samples. We observed that APP is expressed at higher levels in lymphoblastoid cell lines from patients with FXS compared to controls ( Figure 7A ). In addition, the analysis of elderly human (F) Surface APP is decreased in the Fmr1 KO cortical neurons. Proteins were biotinylated and captured with streptavidin-beads (input 1/10, lanes 1, 2 and 5; surface ''sur'' lanes 3, 4, and 6). APP, GAPDH, NR2A, and FMRP levels were analyzed by WB. The histograms show the quantification. The changes of total versus surface APP are expressed as ratio of the WT. The bars represent the SEM (*p < 0.05, **p < 0.01, one-sample t test) (n = 4). (G) sAPP levels are increased in cortical neurons. sAPP levels were analyzed by WB in the conditioned medium from WT and KO cortical neurons. The histograms show the quantification of APP protein levels normalized to the Coomassie. This ratio was set to 1 in the WT mice. The bars represent the SEM (*p < 0.05, Student's t test) (n = 4). postmortem brains from FXS and control individuals revealed that a reduction in the levels of FMRP alters APP expression in the cortex ( Figure 7B ; Table S1 ) and cerebellum (data not shown). APP mRNA levels did not change significantly ( Figures  S1C and S1D ). The dysregulation of APP protein levels are consistent with our observation in adult Fmr1 KO brains (Figure 1) . No significant changes were detected in ADAM10 levels in human postmortem brains (average age of 60) or immortalized (A) ADAM10 expression is higher in Fmr1 KO mice than in WT. Representative WB showing the ADAM10 protein levels in WT and KO cortices (black arrowheads: mature proteins and white arrowheads: prodomain containing proteins). The histograms show the quantification of ADAM10 and APP protein levels normalized to GAPDH levels expressed as ratio of the WT. The bars represent the SEM (*p < 0.05, **p < 0.01, Student's t test) (n = 3). (B) ADAM10 expression is increased in synaptoneurosomes (Syn) from KO mice. Representative WB showing ADAM10, ADAM9, and ADAM17 expression levels in the WT and the KO mice (black arrowheads: mature protein and white arrowhead: immature protein). The histograms represent the quantification of protein levels normalized to GAPDH levels expressed as ratio of the WT. The bars represent the SEM (**p < 0.01, Student's t test) (n = 4). (C) ADAM10 expression during development. ADAM10 protein levels were detected in WT and KO brain cortex extracts at P14, P21, P30, and P90. The GAPDH was used as normalizer. The bars represent the SEM ( **p < 0.01, Student's t test) (n = 3). (B) Spine density of the different spine types. The bars represent the SEM (***p < 0.001, non-significant = n.s., one-way ANOVA followed by post hoc Bonferroni correction) (n = 10 neurons from at least two different cultures). For each condition, 350-500 spines were analyzed. (C) Density of the mature and immature spines. The spine morphology was used to discriminate the spine types. See Figure S5 . The bars represent the SEM (***p < 0.001, one-way ANOVA followed by post hoc Bonferroni correction) (n = 10 neurons from at least two different cultures). For each condition, 350-500 spines were analyzed. See also Figures S4 and S5. lymphoblastoid cells from FXS compared to control individuals. These findings are consistent to what we observed in the mouse model where a development specific dysregulation of ADAM10 was observed in juvenile mice only ( Figure 3C ). Because human postmortem brains from adolescent FXS were not available, we analyzed APP and ADAM10 expression in primary fibroblasts obtained from adolescent and adult patients with FXS. Importantly, in these cells, APP and ADAM10 were both upregulated in FXS patients (average age of 25) ( Figure 7C ), and additionally, the sAPPa product of ADAM10 activity was also increased in cells from FXS patients ( Figure 7D ). Finally, FMRP was IP from human control fibroblasts and the bound mRNAs were analyzed by RT-PCR, confirming that APP and ADAM10 mRNAs are associated to FMRP ( Figure 7E ). These findings demonstrate that APP and ADAM10 are also dysregulated in FXS human patients, and that ADAM10 dysregulation is possibly under developmental regulation in human patients.
DISCUSSION
Despite significant interest in the physiological functions of APP and its processed forms in the CNS, the mechanisms underlying APP developmental regulation and function(s) remain elusive. Dysregulation of APP and its metabolites, sAPPa and Ab, have been observed in AD, autism, and Down syndrome (Glenner and Wong, 1984; Ray et al., 2011) , suggesting that dysregulation of APP may have a key effect on neuronal pathologies marked by neurodegeneration and deficits in neurodevelopment.
Here, we show that sAPPa contributes to the three major hallmarks of FXS; namely, increased protein synthesis, aberrant spine morphology, and altered synaptic function and behavior. The expression of both APP and the a-secretase ADAM10 is controlled by FMRP during synaptogenesis (Figures 1, 3 , and 8). Both proteins are upregulated in the absence of FMRP due to the lack of translational control on the respective mRNAs (Figures 3 and 8) . Therefore, in FXS the unbalanced APP processing elicits excessive production of sAPPa (Figures 2 and 8) .
The impairment in protein synthesis is linked to aberrant synaptic structure and plasticity in FXS (Bagni et al., 2012) . We now show that the a-secretase activity is needed for the APPmediated increase in protein synthesis, and administration of sAPPa causes FXS-like deficits, such as spine formation, maturation, and plasticity (Figures 4, 5, 6, and 8) . Moreover, genetic reduction of APP or ADAM10 activity is sufficient to reduce protein synthesis in Fmr1 KO neurons (Figure 6 ). Aberrant LTD in FXS mice is also rescued by the genetic downregulation of APP (Westmark et al., 2011) , and ADAM10 activity has been related to LTD and spine morphology (Musardo et al., 2013; Prox et al., 2013) , strongly suggesting that ADAM10-mediated APP cleavage is required in synaptic plasticity. Moreover, sAPPa is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice (Ring et al., 2007) . Reduction of ADAM10 activity in vivo using a peptide inhibitor (Marcello et al., 2007) in juvenile Fmr1 KO neurons restored normal sAPPa levels, prevented the exaggerated mGluR-LTD, and rescued behavioral deficits (Figures 6 and 8 ).
In conclusion, excessive sAPPa, rather than full-length APP or Ab, is involved in the synaptic pathology in FXS. Of relevance for the disease, we found that APP, ADAM10, and sAPPa levels were dysregulated in human samples (Figure 7) . Exaggerated mGluR1/5-dependent protein synthesis is one of the main features of FXS and is directly correlated to the increased mGluR-LTD (Bear et al., 2004) . Throughout our studies, we have come full circle on a disease that over the last two decades has confronted us with an endless complexity. Lack of the translational repressor FMRP causes an increase of the mGluR1/5 signaling that promotes sAPPa release; in turn, sAPPa triggers ERK1/2 phosphorylation and sustains mGluR1/ 5 activation and protein synthesis (Figures 5 and 8) . Blockade of the mGluR5 (Osterweil et al., 2010) or genetic reduction of APP reduces protein synthesis in the Fmr1 KO ( Figure 5) .
Finally, our findings go beyond the role of APP and sAPPa in FXS: we provide new insights into the regulation of the non-amyloidoigenic pathway and its role in synaptic function during a critical developmental window. APP protein expression and processing are developmentally controlled, as levels are higher in the second postnatal week during synaptogenesis and then decline when mature connections are completed (Moya et al., 1994) . We demonstrate that FMRP regulates APP expression and processing only after the second postnatal week (Figures 1 and 2) , concomitantly with the physiological decrease in APP. We propose that FMRP may intervene to avoid excessive APP and ADAM10 expression and sAPPa production during a critical period for synaptic stabilization and elimination (Yuste, 2013) .
Our findings in humans ( Figure 7) suggest that, similarly to the mouse model, the excess of APP and sAPPa triggers excessive protein synthesis, impaired synaptic LTD, leading to a detrimental effect on spine and brain function.
Considering the synaptic expression of APP, the neurotrophic function suggested for sAPPa (Hoe et al., 2012; Mü ller and Zheng, 2012) and its role in pruning (Olsen et al., 2014) , the increased expression of sAPPa during synaptogenesis (Moya et al., 1994) could contribute to brain overgrowth and to defects in net spine pruning responsible for the abnormally high synaptic density observed in ASD (Tang et al., 2014) . FXS is a neurodevelopmental disorder and patients with FXS have a high incidence of ASD. Children with severe autism and Fragile X express elevated levels of sAPPa (Erickson et al., 2014; Ray et al., 2011) , consistent with the hypothesis for a sAPPa-mediated anabolic pathway in ASD (Lahiri et al., 2013) . Therefore, it is tempting to hypothesize that alteration of the APP non-amyloidoigenic pathway might be a shared feature of several neurodevelopmental disorders.
While the effect of sAPPa predominates, the excessive a-secretase activity upregulates CTFa and downregulates Ab by competing with the b-secretase pathway or directly inhibiting BACE1 activity (Obregon et al., 2012) . The APP CTFs can regulate signal transduction and apoptosis (Schettini et al., 2010) and we cannot exclude the possibility that their dysregulation also contributes to the FXS phenotypes. On the other hand, the amyloidogenic pathway is downregulated during synaptogenesis and we can therefore exclude a pathogenic effect of Ab accumulation (Figure 2) . On the contrary, since Ab may stimulate neurotransmission (Morley et al., 2010) , lower Ab levels in FXS could exacerbate intellectual deficits. Increased APP levels are correlated with Ab deposition in the brain; however, a mild increase in APP expression contributes to AD risk only at later ages (Brouwers et al., 2006) . In old FXS mice, the equilibrium of the amyloidoigenic and non-amyloidoigenic pathways changes and there is a mild accumulation of Ab (Figure 2) . Further studies are required to address if the increase in APP levels observed in human FXS brains is sufficient to cause AD symptoms. Of note, higher incidence of dementia and cognitive deficits similar to those of AD was reported in elderly FXTAS patients with a decrease in FMRP expression (Seritan et al., 2008; Tassone et al., 2012) .
Since the identification of the gene causing FXS in 1991, understanding and knowledge of the FMRP function(s) have increased (Bassell and Warren, 2008) , but to date an effective therapy is still missing. Several therapeutic approaches for FXS have been explored and taken into clinical trials, however, several have been discontinued (https//:www.clinicaltrials.gov). Over the past few years, the FXS features observed in mice have been rescued through genetic reduction of single dysregulated genes (Bagni et al., 2012) . The consequence of FMRP binding to several mRNAs in the brain (Pasciuto and Bagni, 2014b ) is the impaired expression of a larger number of protein therefore identification of a key pathway, deregulated during a critical period of synaptic formation and brain connectivity, is therefore of utmost importance.
Although there are no pharmacological approaches to reduce APP expression, reduction of ADAM10 activity may provide an alternative approach for modulating sAPPa levels at synapses. We reduced ADAM10 synaptic localization and activity using the TAT-Pro peptide, a treatment previously shown to affect synaptic morphology and plasticity (Malinverno et al., 2010; Marcello et al., 2007) . Treatment of juvenile Fmr1 KO mice reduced APP a-cleavage, normalized enhanced LTD, and some behavioral deficits (Figures 6 and 8) . Because of the high levels of sAPPa found in the blood of autistic patients and in Fragile X children (Erickson et al., 2014) , and the prevalence of autistic features in FXS, it is tempting to hypothesize that the activation of the ADAM10 pathway, leading to an excess of sAPPa production, is shared between patients with FXS and ASD. Finally, FXS symptoms suggest an early postnatal/childhood disruption of the brain wiring that may underlie ASD like features (La Fata et al., 2014; Romano et al., 2014) . Based on our studies, we believe that the developmental period around synaptogenesis offers potentials for interventions to ameliorate some of the deficits observed in patients with FXS.
EXPERIMENTAL PROCEDURES Human Samples
Patients' samples were received through clinical collaborators and co-authors of this study. Informed consent and ethical approval are available on site and at KU Leuven (Belgium).
Mice and Animal Care
Animal care was conducted conforming to institutional guidelines in compliance with international laws and policies (DL N116, GU, suppl 40, 18-2-1992; Belgian law KoninklijkBesluit (K.B.), 1993 and K.B, 2004; the European Community Council Directive 86/609, OJa L 358, 1, 1987 ; the National Institutes of Health Guide for the Care and Use of Laboratory Animals, US National Research Council, 1996) . Studies were approved by the Institutional Ethical Board at the University of Leuven, Belgium. P7, P14, P21, P30, and P90 C57BL/6 WT and Fmr1 KO male mice (Bakker, 1994) , APP KO (Li et al., 1996) , and ADAM10
Het (Jorissen et al., 2010) were used in this study.
Animal Treatment P19 and 20 mice received a single intraperitoneal injection of either TAT-Pro (2 or 3 nmol/g) or TAT-Ala peptide (2 or 3 nmol/g) diluted in sterile saline solution (Marcello et al., 2007) . Animals were euthanized after 18 hr and the brains were rapidly removed. The TAT-Pro 709-729 ADAM10 inhibitory peptide (TATPro) and TAT-Ala 709-729 ADAM10 control peptide (TAT-Ala) were generated as previously described (Marcello et al., 2007) . , and Hypoxanthineribosyltransferase (HPRT) mRNAs was set at 1 in each experiment (n = 3 controls, two independent experiments). The bars represent the SEM (*p < 0.05, one sample t test).
Neuronal Culture Preparation and Treatments
Mouse primary cortical neurons were prepared as previously described (De Rubeis et al., 2013) . See Supplemental Information for details and treatments.
Human Fibroblasts and Lymphoblastoid Cell Lines
Fibroblasts from FXS subjects (n = 8, age range 12-37 years) were obtained from the University Hospital of Lausanne, while fibroblasts from healthy volunteers (n = 7, age range 15-42 years) were purchased from the Coriell Institute for Medical Research and from Lonza. Lymphoblastoid cell lines (CTR n = 6 and FXS n = 6) were obtained from University of California, Davis (UC Davis) (USA). See Supplemental Information for growth conditions.
Brain Protein Extracts
Brains lysates were prepared as previously described (Napoli et al., 2008) . For details see the Supplemental Information. For enriched membrane proteins, 1% sodium deoxycholate was added and the extracts were incubated for 30 min on ice and centrifuged. For total protein analysis, the brains or cells were homogenized in Laemmli buffer as previously described (Napoli et al., 2008) .
Synaptoneurosomes
Synaptoneurosomes were prepared as previously described (Pilo Boyl et al., 2007) . For details see the Supplemental Information.
WB
Standard methodologies were used. Antibodies list and usage is described in the Supplemental Information.
SUnSET A protein synthesis assay was performed using the SUnSET method (Schmidt et al., 2009) . For details see the Supplemental Information.
DNA Constructs
The pEGFP plasmid used is commercially available (Clontech). The pLentiLox3.7 (pLL3.7) vector containing the shRNA against APP (targeting nt 538-556 of APP Genbank:X59379.1) has been previously described (Hoe et al., 2009) ; it is specific for both mouse and rat APP and was kindly provided by Dr. Daniel Pak (Georgetown University Medical Center).
Transfection
Neurons were transfected at 8 days in culture using the calcium phosphate method as previously described (De Rubeis et al., 2013). Neurons were fixed 6 days later with 4% paraformaldehyde/sucrose EDTA magnesium PFA/ SEM (4% PFA, 0.12 M sucrose, 3 mM EGTA, and 2 mM MgCl2 in PBS). Confocal images were acquired and analyzed as described in the Supplemental Information.
Immunofluorescence
For experimental details and antibodies list and usage see the Supplemental Information.
IP and RT-PCR IP protocol was modified from Napoli et al. (2008) . For details see the Supplemental Information.
Polysome-mRNPs Analysis
Polysome-mRNPs have been isolated as previously described (Zalfa et al., 2007) . For details see the Supplemental Information.
RT-Quantitative PCR Using the SYBRGreen Method
Real-Time PCR was performed using the SYBRGreen mix and a Light Cycler 480 (Roche).
Biotinylation Assay
Biotinylation of cell surface proteins was performed as previously described (Hiltunen et al., 2006) . For details see the Supplemental Information.
Ab 40-42 ELISA The brains were solubilized in guanidine hydrochloride, and Ab was detected using a sandwich ELISA assay according to the manufacturer's specifications (WACO).
Brain Fractionation
See the Supplemental Information and Figure S2 .
Electrophysiology
The mGluR mediated LTD was induced as previously described (Tambuyzer et al., 2013) . For details see the Supplemental Information.
Behavioral Tests
All behavioral experiments were performed with P24 and 25 male mice and blind to the genotype and treatment. For experimental details see the Supplemental Information.
Statistics
Comparisons between the two groups were performed using one-sample or two-sample two-tailed Student's t tests. One-way ANOVA followed by a proteins. This lack of translational control results in combined upregulation of APP and ADAM10 and accumulation of sAPPa. sAPPa triggers ERK1/2 phosphorylation and sustains mGluR1/5 activation and protein translation. Dysregulation of the APP-ADAM10 processing pathway leads to FXS deficits. Finally, reduction of ADAM10 trafficking/activity at synapses, using the TAT-Pro peptide, restores sAPPa levels, mGluR-LTD, protein expression, and behavioral deficits in FXS mice.
post hoc Holm's, Bonferroni's, or Sidak's multiple comparisons test was performed. Distributions were analyzed using the Pearson's chi-square (c 2 ) test.
Comparisons between the cumulative probability plots were performed using a two-sample Kolmogorov-Smirnov (K-S) test. Significance was denoted as p < 0.05. Bars represent the SEM. Electrophysiological data were analyzed using repeated-measures ANOVA. 
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